位置:首页 > 产品库 > 重组泛素结合酶E2 230K蛋白
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
重组泛素结合酶E2 230K蛋白
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。

Recombinant UBE2O
Recombinant ubiquitin conjugating enzyme E2 O protein
基因名:

UBE2O


产品别名:

E2-230K; UBE2O; ubiquitin conjugating enzyme E2 O; ubiquitin conjugating enzyme E2 O; (E3-independent) E2 ubiquitin-conjugating enzyme; E2/E3 hybrid ubiquitin-protein ligase UBE2O; ubiquitin carrier protein O; ubiquitin conjugating enzyme E2O; ubiquitin-conjugating enzyme E2 of 230 kDa; ubiquitin-conjugating enzyme E2-230K; ubiquitin-protein ligase O; 泛素结合酶E2 230K;


背景信息:
UBE20, also known as E2-230K, is a 1,292 amino acid member of the uniquitin-conjugating enzyme family that is involved in protein modification. Expressed predominately in heart and skeletal muscle, UBE2O functions to catalyze the ATP-dependent covalent attachment of ubiquitin to select proteins, thereby targeting the ubiquitinated proteins for proteasomal degradation. The gene encoding UBE2O maps to human chromosome 17, which comprises over 2.5% of the human genome and encodes over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes.

标签:His-tag   
分类:Recombinant  
类型:Protein   
偶联物:Unconjugated
内毒素水平:按批次,参阅瓶身标签
性状:Liquid
浓度:Batch dependent (Please refer to the vial label for the specific concentration.)
纯化类型:purified
内含物:不含防腐剂
应用:Positive Control;Immunogen;SDS-PAGE;WB.
储存:2-8°C不超过一个月,-80°C不超过12个月。避免反复冻融。
注意事项:仅供实验室使用。不适用于人类或动物的任何临床,治疗或诊断用途。不适合动物或人类食用。

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024